Table of Contents Author Guidelines Submit a Manuscript
Pathology Research International
Volume 2011, Article ID 736425, 8 pages
http://dx.doi.org/10.4061/2011/736425
Research Article

Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance

1Division of Endocrinology, Department of Medicine, Stony Brook University Medical Center, HSC T15-060, Stony Brook, NY 11794-8154, USA
2Department of Surgery, Stony Brook University Medical Center, Stony Brook, NY 11794-8154, USA

Received 28 December 2010; Accepted 21 February 2011

Academic Editor: Liron Pantanowitz

Copyright © 2011 Dennis C. Mynarcik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. C. Mynarcik, M. A. McNurlan, R. T. Steigbigel, J. Fuhrer, and M. C. Gelato, “Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy,” Journal of Acquired Immune Deficiency Syndromes, vol. 25, no. 4, pp. 312–321, 2000. View at Google Scholar · View at Scopus
  2. A. Carr, K. Samaras, A. Thorisdottir, G. R. Kaufmann, D. J. Chisholm, and D. A. Cooper, “Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study,” The Lancet, vol. 353, no. 9170, pp. 2093–2099, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. G. M. N. Behrens, A. R. Boerner, K. Weber et al., “Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy,” Journal of Clinical Investigation, vol. 110, no. 9, pp. 1319–1327, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. J. C. Lo, M. R. Kazemi, P. Y. Hsue et al., “The relationship between nucleosicle analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection,” Clinical Infectious Diseases, vol. 41, no. 9, pp. 1335–1340, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Mulligan, C. Grunfeld, V. W. Tai et al., “Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection,” Journal of Acquired Immune Deficiency Syndromes, vol. 23, no. 1, pp. 35–43, 2000. View at Google Scholar · View at Scopus
  6. J. P. Després, B. Lamarche, P. Mauriège et al., “Hyperinsulinemia as an independent risk factor for ischemic heart disease,” The New England Journal of Medicine, vol. 334, no. 15, pp. 952–957, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. S. M. Haffner, R. D'Agostino, L. Mykkänen et al., “Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study,” Diabetes Care, vol. 22, no. 4, pp. 562–568, 1999. View at Google Scholar · View at Scopus
  8. S. M. Haffner, “Impaired glucose tolerance—is it relevant for cardiovascular disease?” Diabetologia, vol. 40, supplement 2, pp. S138–S140, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Garg, “Dyslipoproteinemia and diabetes,” Endocrinology and Metabolism Clinics of North America, vol. 27, no. 3, pp. 613–625, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. G. A. Bray, “Body fat distribution and the distribution and the distribution of scientific knowledge,” Obesity Research, vol. 4, no. 2, pp. 189–192, 1996. View at Google Scholar
  11. N. Friis-Møller, R. Weber, P. Reiss et al., “Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study,” AIDS, vol. 17, no. 8, pp. 1179–1193, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. C. Gelato, D. C. Mynarcik, J. L. Quick et al., “Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study,” Journal of Acquired Immune Deficiency Syndromes, vol. 31, no. 2, pp. 163–170, 2002. View at Google Scholar · View at Scopus
  13. T. Feldt, M. Oette, A. Kroidl et al., “Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome,” Infection, vol. 34, no. 2, pp. 55–61, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Tomažič, P. Karner, L. Vidmar, M. Matičič, P. M. Sharma, and A. Janež, “Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART,” Acta Dermatovenerologica Alpina, Pannonica et Adriatica, vol. 14, no. 3, pp. 99–105, 2005. View at Google Scholar · View at Scopus
  15. J. P. Van Wijk, E. J. De Koning, M. C. Cabezas, J. Op't Roodt, J. Joven, and T. J. Rabelink, “Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial,” Annals of Internal Medicine, vol. 143, pp. 337–346, 2005. View at Google Scholar · View at Scopus
  16. C. Hadigan, S. Yawetz, A. Thomas, F. Havers, P. E. Sax, and S. Grinspoon, “Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial,” Annals of Internal Medicine, vol. 140, no. 10, pp. 786–794, 2004. View at Google Scholar · View at Scopus
  17. C. Hadigan, C. Corcoran, N. Basgoz, B. Davis, P. Sax, and S. Grinspoon, “Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial,” Journal of the American Medical Association, vol. 284, no. 4, pp. 472–477, 2000. View at Google Scholar · View at Scopus
  18. E. D. Rosen, P. Sarraf, A. E. Troy et al., “PPARγ is required for the differentiation of adipose tissue in vivo and in vitro,” Molecular Cell, vol. 4, no. 4, pp. 611–617, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Carr, K. Samaras, S. Burton et al., “A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors,” AIDS, vol. 12, no. 7, pp. F51–F58, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Hadigan, K. Miller, C. Corcoran, E. Anderson, N. Basgoz, and S. Grinspoon, “Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 6, pp. 1932–1937, 1999. View at Google Scholar · View at Scopus
  21. J. Sutinen, A. M. Häkkinen, J. Westerbacka et al., “Rosiglitazone in the treatment of HAART-associated lipodystrophy—a randomized double-blind placebo-controlled study,” Antiviral Therapy, vol. 8, no. 3, pp. 199–207, 2003. View at Google Scholar · View at Scopus
  22. A. Carr, C. Workman, D. Carey et al., “No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 363, no. 9407, pp. 429–438, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Seimandi, G. Lemaire, A. Pillon et al., “Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands,” Analytical Biochemistry, vol. 344, no. 1, pp. 8–15, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Koyama, J. K. Boueres, W. Han et al., “5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 10, pp. 1801–1804, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Sutinen, K. Kannisto, E. Korsheninnikova et al., “Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy,” American Journal of Physiology, vol. 286, no. 6, pp. E941–E949, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. D. J. Evans, R. Murray, and A. H. Kissebah, “Relationship between skeletal muscle insulin resistance, insulin mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography,” Journal of Clinical Investigation, vol. 74, no. 4, pp. 1515–1525, 1984. View at Google Scholar · View at Scopus
  27. R. A. DeFronzo, J. D. Tobin, and R. Andres, “Glucose clamp technique: a method for quantifying insulin secretion and resistance,” The American journal of physiology, vol. 237, no. 3, pp. E214–223, 1979. View at Google Scholar · View at Scopus
  28. S. D. Wise, M. F. Nielsen, P. E. Cryer, and R. A. Rizza, “Overnight normalization of glucose concentrations improves hepatic but not extrahepatic insulin action in subjects with type 2 diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 7, pp. 2461–2469, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. N. N. Abumrad, D. Rabin, M. P. Diamond, and W. W. Lacy, “Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man,” Metabolism, vol. 30, no. 9, pp. 936–940, 1981. View at Google Scholar · View at Scopus
  30. R. S. Staron, F. C. Hagerman, R. S. Hikida et al., “Fiber type composition of the vastus lateralis muscle of young men and women,” Journal of Histochemistry and Cytochemistry, vol. 48, no. 5, pp. 623–629, 2000. View at Google Scholar · View at Scopus
  31. H. J. Green, J. A. Thomson, and W. D. Daub, “Fiber composition, fiber size and enzyme activities in vastus lateralis of elite athletes involved in high intensity exercise,” European Journal of Applied Physiology and Occupational Physiology, vol. 41, no. 2, pp. 109–117, 1979. View at Google Scholar · View at Scopus
  32. B. I. Frohnert and D. A. Bernlohr, “Regulation of fatty acid transporters in mammalian cells,” Progress in Lipid Research, vol. 39, no. 1, pp. 83–107, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Way, W. W. Harrington, K. K. Brown et al., “Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues,” Endocrinology, vol. 142, no. 3, pp. 1269–1277, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. R. A. DeFronzo, E. Jacot, E. Jequier, E. Maeder, J. Wahren, and J. P. Felber, “The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization,” Diabetes, vol. 30, no. 12, pp. 1000–1007, 1981. View at Google Scholar · View at Scopus
  35. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. A. L. Bookout, Y. Jeong, M. Downes, R. T. Yu, R. M. Evans, and D. J. Mangelsdorf, “Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network,” Cell, vol. 126, no. 4, pp. 789–799, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPARγ gene,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Hammarstedt, V. Rotter Sopasakis, S. Gogg, P. A. Jansson, and U. Smith, “Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects,” Diabetologia, vol. 48, no. 1, pp. 96–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo, “Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4312–4319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Tonelli, W. Li, P. Kishore et al., “Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes,” Diabetes, vol. 53, no. 6, pp. 1621–1629, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. U. B. Pajvani, M. Hawkins, T. P. Combs et al., “Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity,” Journal of Biological Chemistry, vol. 279, no. 13, pp. 12152–12162, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Yamauchi, Y. Nio, T. Maki et al., “Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions,” Nature Medicine, vol. 13, no. 3, pp. 332–339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. A. R. Nawrocki, M. W. Rajala, E. Tomas et al., “Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists,” Journal of Biological Chemistry, vol. 281, no. 5, pp. 2654–2660, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. A. H. Berg, T. P. Combs, and P. E. Scherer, “ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism,” Trends in Endocrinology and Metabolism, vol. 13, no. 2, pp. 84–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. J. K. Kim, J. J. Fillmore, O. Gavrilova et al., “Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice,” Diabetes, vol. 52, no. 6, pp. 1311–1318, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. A. L. Hevener, W. He, Y. Barak et al., “Muscle-specific Pparg deletion causes insulin resistance,” Nature Medicine, vol. 9, no. 12, pp. 1491–1497, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. J. R. Zierath, J. W. Ryder, T. Doebber et al., “Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action,” Endocrinology, vol. 139, no. 12, pp. 5034–5041, 1998. View at Google Scholar · View at Scopus
  48. K. S. Park, T. P. Ciaraldi, L. Abrams-Carter, S. Mudaliar, S. E. Nikoulina, and R. R. Henry, “PPAR-γ gene expression is elevated in skeletal muscle of obese and II diabetic subjects,” Diabetes, vol. 46, no. 7, pp. 1230–1234, 1997. View at Google Scholar · View at Scopus
  49. M. Loviscach, N. Rehman, L. Carter et al., “Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action,” Diabetologia, vol. 43, no. 3, pp. 304–311, 2000. View at Google Scholar · View at Scopus
  50. N. B. Ruderman and D. Dean, “Malonyl CoA, long chain fatty acyl CoA and insulin resistance in skeletal muscle,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 9, no. 2-4, pp. 295–308, 1998. View at Google Scholar · View at Scopus
  51. H. M. Wilmsen, T. P. Ciaraldi, L. Carter, N. Reehman, S. R. Mudaliar, and R. R. Henry, “Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects,” American Journal of Physiology, vol. 285, no. 2, pp. E354–E362, 2003. View at Google Scholar · View at Scopus
  52. C. R. Benton, D. P. Y. Koonen, J. Calles-Escandon et al., “Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle,” Journal of Physiology, vol. 573, no. 1, pp. 199–210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Zhang, D. I. W. Phillips, C. Wang, and C. D. Byrne, “Human skeletal muscle PPARα expression correlates with fat metabolism gene expression but not BMI or insulin sensitivity,” American Journal of Physiology, vol. 286, no. 2, pp. E168–E175, 2004. View at Google Scholar · View at Scopus